GlassScriptPhysician profile
Sanjeev Bhatia
NPI 1275513491
$950.41
in general payments reported to CMS, 2019-2025
22 companies · $151 in 2025
The $151 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $93.64 · 2020: $11.90 · 2021: $138 · 2022: $299 · 2023: $80.47 · 2024: $176 · 2025: $151.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $408.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $407.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $277.51 | 2022-2025 | |
| Madrigal Pharmaceuticals | $77.04 | 2025 | Rezdiffra |
| Abbvie INC. | $71.28 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $70.17 | 2019-2024 | Airsupra |
| Shield Therapeutics INC | $51.85 | 2023-2024 | Accrufer |
| Boehringer Ingelheim Pharmaceuticals, INC. | $45.28 | 2021 | |
| Tactile Systems Technology INC | $44.51 | 2019-2025 | Flexitouch Plus, Nimbl |
| Pfizer INC. | $37.05 | 2022-2024 | |
| Novo Nordisk INC | $37.02 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $27.42 | 2023-2024 | Xifaxan, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $24.94 | 2022 | |
| Merck Sharp & Dohme LLC | $23.67 | 2024 | Capvaxive |
| Abbott Laboratories | $20.98 | 2021 | |
| Lilly USA, LLC | $20.82 | 2022 | |
| Glaxosmithkline, LLC. | $18.76 | 2023 | Arexvy, Trelegy Ellipta |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $17.26 | 2019 | |
| Harmony Biosciences LLC | $16.90 | 2022 | |
| Medtronic, INC. | $15.21 | 2025 | Inceptiv |
| Teva Pharmaceuticals USA, INC. | $14.40 | 2023 | Austedo |
| Amgen INC. | $14.22 | 2024 | Tavneos |
| Paratek Pharmaceuticals, INC. | $12.70 | 2022 | |
| Novartis Pharmaceuticals Corporation | $11.42 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sanjeev Bhatia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.